US 11,654,296 B2
Medical apparatus and method
Duncan John Hill, Sedgefield (GB); and Thomas Snell, Sedgefield (GB)
Assigned to Polyphotonix Limited, Sedgefield (GB)
Filed by Polyphotonix Limited, Sedgefield (GB)
Filed on Jul. 13, 2020, as Appl. No. 16/927,072.
Application 16/927,072 is a continuation of application No. 14/916,863, previously published as PCT/GB2014/052627, filed on Aug. 29, 2014.
Claims priority of application No. 1315836 (GB), filed on Sep. 5, 2013.
Prior Publication US 2020/0346031 A1, Nov. 5, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61N 5/06 (2006.01)
CPC A61N 5/0622 (2013.01) [A61N 2005/0627 (2013.01); A61N 2005/0648 (2013.01); A61N 2005/0652 (2013.01); A61N 2005/0653 (2013.01); A61N 2005/0656 (2013.01); A61N 2005/0662 (2013.01); A61N 2005/0667 (2013.01)] 7 Claims
OG exemplary drawing
1. A medical apparatus for reducing vascular endothelial growth factor expression for treating diabetic retinopathy or age related macular degeneration, the apparatus comprising:
a radiation source for emitting electromagnetic radiation towards one or both eyes of a patient;
wherein the apparatus is configured to emit electromagnetic radiation having a ratio of scotopic luminous intensity to photopic luminous intensity of at least 3:1,
wherein the electromagnetic radiation reaching the eye or eyes of the patient has a range of wavelengths and less than 3% of the total radiation has a wavelength less than 470 nm.